Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Sexual dysfunction factors in patients with schizophrenia treated with second generation antipsychotics: not only prolactin.

Martín JC, Acuña MJ, Labrador J, Blanco M, Casas C.

Actas Esp Psiquiatr. 2018 Nov;46(6):217-25. Epub 2018 Nov 1.

2.

Ancient lowland Maya complexity as revealed by airborne laser scanning of northern Guatemala.

Canuto MA, Estrada-Belli F, Garrison TG, Houston SD, Acuña MJ, Kováč M, Marken D, Nondédéo P, Auld-Thomas L, Castanet C, Chatelain D, Chiriboga CR, Drápela T, Lieskovský T, Tokovinine A, Velasquez A, Fernández-Díaz JC, Shrestha R.

Science. 2018 Sep 28;361(6409). pii: eaau0137. doi: 10.1126/science.aau0137.

PMID:
30262469
3.

Blockade of Bradykinin receptors worsens the dystrophic phenotype of mdx mice: differential effects for B1 and B2 receptors.

Acuña MJ, Salas D, Córdova-Casanova A, Cruz-Soca M, Céspedes C, Vio CP, Brandan E.

J Cell Commun Signal. 2018 Sep;12(3):589-601. doi: 10.1007/s12079-017-0439-x. Epub 2017 Dec 17.

4.

The pro-fibrotic connective tissue growth factor (CTGF/CCN2) correlates with the number of necrotic-regenerative foci in dystrophic muscle.

Morales MG, Acuña MJ, Cabrera D, Goldschmeding R, Brandan E.

J Cell Commun Signal. 2018 Mar;12(1):413-421. doi: 10.1007/s12079-017-0409-3. Epub 2017 Sep 8.

5.

Analysis of Pathological Activities of CCN2/CTGF in Muscle Dystrophy.

Acuña MJ, Brandan E.

Methods Mol Biol. 2017;1489:513-521.

PMID:
27734402
6.

Angiotensin-(1-7) attenuates disuse skeletal muscle atrophy in mice via its receptor, Mas.

Morales MG, Abrigo J, Acuña MJ, Santos RA, Bader M, Brandan E, Simon F, Olguin H, Cabrera D, Cabello-Verrugio C.

Dis Model Mech. 2016 Apr;9(4):441-9. doi: 10.1242/dmm.023390. Epub 2016 Feb 5.

7.

Transforming growth factor type-β inhibits Mas receptor expression in fibroblasts but not in myoblasts or differentiated myotubes; Relevance to fibrosis associated to muscular dystrophies.

Cofre C, Acuña MJ, Contreras O, Morales MG, Riquelme C, Cabello-Verrugio C, Brandan E.

Biofactors. 2015 Mar-Apr;41(2):111-20. doi: 10.1002/biof.1208. Epub 2015 Mar 23. Erratum in: Biofactors. 2015 May 6;41(3):209.

PMID:
25809912
8.

ACE2 is augmented in dystrophic skeletal muscle and plays a role in decreasing associated fibrosis.

Riquelme C, Acuña MJ, Torrejón J, Rebolledo D, Cabrera D, Santos RA, Brandan E.

PLoS One. 2014 Apr 2;9(4):e93449. doi: 10.1371/journal.pone.0093449. eCollection 2014.

9.

Restoration of muscle strength in dystrophic muscle by angiotensin-1-7 through inhibition of TGF-β signalling.

Acuña MJ, Pessina P, Olguin H, Cabrera D, Vio CP, Bader M, Muñoz-Canoves P, Santos RA, Cabello-Verrugio C, Brandan E.

Hum Mol Genet. 2014 Mar 1;23(5):1237-49. doi: 10.1093/hmg/ddt514. Epub 2013 Oct 24.

PMID:
24163134
10.

Transforming growth factor type beta 1 increases the expression of angiotensin II receptor type 2 by a SMAD- and p38 MAPK-dependent mechanism in skeletal muscle.

Painemal P, Acuña MJ, Riquelme C, Brandan E, Cabello-Verrugio C.

Biofactors. 2013 Jul-Aug;39(4):467-75. doi: 10.1002/biof.1087. Epub 2013 Mar 5.

PMID:
23460581
11.

Angiotensin II-induced pro-fibrotic effects require p38MAPK activity and transforming growth factor beta 1 expression in skeletal muscle cells.

Morales MG, Vazquez Y, Acuña MJ, Rivera JC, Simon F, Salas JD, Alvarez Ruf J, Brandan E, Cabello-Verrugio C.

Int J Biochem Cell Biol. 2012 Nov;44(11):1993-2002. doi: 10.1016/j.biocel.2012.07.028. Epub 2012 Aug 7.

PMID:
22964022
12.
13.

Fibrotic response induced by angiotensin-II requires NAD(P)H oxidase-induced reactive oxygen species (ROS) in skeletal muscle cells.

Cabello-Verrugio C, Acuña MJ, Morales MG, Becerra A, Simon F, Brandan E.

Biochem Biophys Res Commun. 2011 Jul 8;410(3):665-70. doi: 10.1016/j.bbrc.2011.06.051. Epub 2011 Jun 12.

PMID:
21693104
14.

Proliferation and differentiation of human adipocyte precursor cells: differences between the preperitoneal and subcutaneous compartments.

Fernández M, Acuña MJ, Reyes M, Olivares D, Hirsch S, Bunout D, de la Maza MP.

J Cell Biochem. 2010 Oct 15;111(3):659-64. doi: 10.1002/jcb.22753.

PMID:
20589764
15.

A comparative study of the sexual function of institutionalized patients with schizophrenia.

Acuña MJ, Martín JC, Graciani M, Cruces A, Gotor F.

J Sex Med. 2010 Oct;7(10):3414-23. doi: 10.1111/j.1743-6109.2010.01832.x.

PMID:
20456629
16.

The anti-adipogenic effect of angiotensin II on human preadipose cells involves ERK1,2 activation and PPARG phosphorylation.

Fuentes P, Acuña MJ, Cifuentes M, Rojas CV.

J Endocrinol. 2010 Jul;206(1):75-83. doi: 10.1677/JOE-10-0049. Epub 2010 May 7.

PMID:
20453075
17.

Larger anti-adipogenic effect of angiotensin II on omental preadipose cells of obese humans.

Brücher R, Cifuentes M, Acuña MJ, Albala C, Rojas CV.

Obesity (Silver Spring). 2007 Jul;15(7):1643-6.

18.

Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study.

Alonso SR, Ortiz P, Pollán M, Pérez-Gómez B, Sánchez L, Acuña MJ, Pajares R, Martínez-Tello FJ, Hortelano CM, Piris MA, Rodríguez-Peralto JL.

Am J Pathol. 2004 Jan;164(1):193-203.

19.

[A critical study of the influence of negative symptoms on the therapeutic response in schizophrenia].

Acuña MJ, Martín J, Noval D, Blanco M.

Actas Luso Esp Neurol Psiquiatr Cienc Afines. 1998 Jul-Aug;26(4):209-13. Spanish.

PMID:
9807853

Supplemental Content

Loading ...
Support Center